Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate
Gordon Brown, Sabree Burbage, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Benjamin Lowentritt · 2025
Read Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate by Gordon Brown, Sabree Burbage, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Benjamin Lowentritt (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12755229.txt.
Description
Gordon Brown and co-authors compare two hormone-blocking drugs in Black patients with prostate cancer that has spread but still answers to hormone therapy, in a 2025 study. Deep drops in the PSA marker after treatment signal better outcomes.
Using linked medical records and insurance claims, the team followed 363 patients starting one of the two drugs. By six months, about sixty-five percent on apalutamide had cut PSA by at least ninety percent, against forty-nine percent on abiraterone. The typical time to that deep drop was about three months against nine. The authors note such real-world data in Black patients have been scarce.
Catalog record
| CREATOR | Gordon Brown, Sabree Burbage, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Benjamin Lowentritt |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |